Point72 Asia (Singapore) Pte. Ltd. Janux Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 70 shares of JANX stock, worth $2,613. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70Holding current value
$2,613% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
228Shares Held
55.1MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$387 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$133 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$131 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$114 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$87.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.56B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...